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Introduction: The most frequently prescribed empirical antibiotic agents for mild and 
moderate	diabetic	foot	infections	(DFIs)	are	amino-	penicillins	and	second-	generation	
cephalosporins that do not cover Pseudomonas	spp.	Many	clinicians	believe	they	can	
predict the involvement of Pseudomonas	in	a	DFI	by	visual	and/or	olfactory	clues,	but	
no data support this assertion.








positive	 predictive	 value	 of	 0.18	 and	 negative	 predictive	 value	 0.92.	 Despite	 two	
feedbacks	of	the	interim	results	and	a	2-	year	period,	the	clinicians'	predictive	perfor-
mance did not improve.
Conclusion: The	 combined	 visual	 and	 olfactory	 performance	 of	 experienced	 clini-
cians in predicting the presence of Pseudomonas	in	a	DFI	was	moderate,	with	better	
specificity	than	sensitivity,	and	did	not	improve	over	time.	Further	investigations	are	
needed to determine whether clinicians should use a negative prediction of the pres-
ence of Pseudomonas	in	a	DFI,	especially	in	settings	with	a	high	prevalence	of	pseu-
domonal	DFIs.
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1  |  INTRODUC TION
Diabetic	foot	infections	(DFIs),	including	diabetic	foot	osteomyelitis	
(DFO),	are	common	and	associated	with	substantial	morbidity,	costs	
and antibiotic use.1– 3 When clinicians face the choice of selecting 
an initial empirical antibiotic regimen for most mild and moderate 
DFIs,4,5	 one	 pathogen	 has	 exceptional	 prominence	 in	 their	 judge-
ment: Pseudomonas aeruginosa.6,7 This is because they perceive 
Pseudomonas	to	be	both	a	common	and	a	highly	antibiotic-	resistant	
pathogen.	 In	 fact,	 microbiological	 surveys	 from	 around	 the	world	
have	shown	that	it	is	a	frequent	isolate	from	DFIs	in	subtropical	re-
gions	(eg	South	[Eastern]	Asia	or	the	Middle	East),	but	far	less	so	in	
temperate	 areas	 (eg	North	America	 and	 Europe).2,5 These studies 
have confirmed that P. aeruginosa is naturally resistant to standard 
antibiotics4	most	 often	 prescribed	 for	mild	 and	moderate	DFIs,4,5 
such	 as	 amino-	penicillins	 or	 first-	 and	 second-	generation	 cepha-
losporins.	 The	 guidelines	on	DFI	 published	by	both	 the	 Infectious	
Diseases	Society	of	America	(IDSA)4	and	the	International	Working	
Group	on	the	Diabetic	Foot	(IWGDF)5 recommend selecting empiric 
anti-	pseudomonal	antibiotic	agents	only	when	P. aeruginosa is a doc-




are able to judge the likelihood of the presence of Pseudomonas in an 
individual	patient.	While	knowing	certain	clinic-	demographic	infor-
mation	(eg	geographical	location,	previous	antimicrobial	treatments	




by detecting certain visual (green colour8)	 and/or	olfactory	 (grape	
fruit– like smell9)	clues.	There	are,	however,	no	data	to	support	this	
widespread	assumption.	 If	accurate,	using	 these	quick,	convenient	
and	 inexpensive	clinical	 findings	could	be	a	major	help	 in	avoiding	
antibiotic	 therapy	 that	 is	 either	 unnecessarily	 broad-	spectrum	 or	
that	fails	to	cover	the	causative	pathogen,	at	least	for	mild	and	mod-
erate	DFIs.	Thus,	we	undertook	a	prospective	observational	study	
to assess the clinical performance of various healthcare providers 
in	our	specialized,	tertiary	centre	for	DFIs	in	predicting	the	clinical	
involvement of Pseudomonas	on	infected	wound	culture.	Of	note,	we	
do not analyse the impact of P. aeruginosa	on	the	DFI	outcomes,	or	
the	prediction	of	pseudomonal	colonization	in	diabetic	foot	ulcers,	
for which a broader literature is available.6,7
2  |  METHODS
2.1  |  Setting
The	 Balgrist	 University	 Hospital	 in	 Zurich	 is	 affiliated	 with	 the	
University	 of	 Zurich	 and	 is	 a	 tertiary	 referral	 centre	 for	 patients	




orthopaedic	 shoe	 factory,	 prosthesis	 specialists	 and	 an	 infectious	
diseases	physician	specialized	in	orthopaedic	infections.10













cases	with	 known	microbiological	 results.	 The	HCW	was,	 however,	
allowed to know the actual empirical antibiotic regimen selected by 
the referring general practitioner and could also use the presence or 
absence of maceration or local ischaemia as a guide to predict the 
presence of Pseudomonas.	In	our	clinical	experience	and	according	to	a	
F I G U R E  1 Photograph	of	a	diabetic	patient	with	mixed	
infection of the foot due to Pseudomonas aeruginosa and three 
other	pathogens.	Please	note	the	absence	of	a	clear	green	colour	
around the infected and ischaemic skin. The colour is rather 
yellowish. Permitted by patient
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widespread	thinking	in	the	world,	Pseudomonas spp. would not cause 
maceration	by	itself,	but	chronic	maceration	can	become	the	habitat	
of nonfermenting rods11 as Pseudomonas	spp.	or	colonized	by	(Gram-	
negative)	anaerobes.12	Our	criterion	standard	to	judge	the	prediction	
was the presence or absence on microbiological clinical cultures of 
Pseudomonas spp,	and/or	the	patient	achieving	clinical	remission	of	DFI	
when treated only with antibiotic agents that were not active against 
Pseudomonas.	 Assessing	 the	 clinical	 evolution	 of	 the	 infection	 was	
an	integral	part	of	the	study.	For	example,	if	the	cultures	grew	P. aer-
uginosa,	among	multiple	other	organisms,	and	the	patient	was	cured	
with	co-	amoxiclav	alone	(without	radical	amputation),13,14 we did not 
consider the Pseudomonas a pathogen. We defined the presence of 
DFI	by	the	IDSA	criteria4 and performed microbiological assessments 
by	 standard	 techniques,	based	on	 the	EUCAST	 recommendations.15 
Our	 Microbiology	 Laboratory	 routinely	 seeks	 and	 reports	 about	
Pseudomonas	spp.	in	cases	of	polymicrobial	DFI.





because several studies have found that olfactory abilities of women 
are superior to those of men.16,17	Moreover,	we	 evaluated	whether	
there	was	an	effect	of	the	result	of	finding	of	Gram-	negative	organ-








to them. This was mostly given orally but was accompanied by distrib-
uting to them an abstract detailing the findings for the Swiss National 
Congress 2020. We gave the surgeons a second presentation of the 
results	 in	 form	of	 a	 lecture	 using	 a	 PowerPoint™	presentation	 (that	
we	mandated	they	attend)	after	we	enrolled	160	episodes	on	20	July	










2.3  |  Statistical analyses
The	 primary	 outcome	 of	 interest	 was	 the	 sensitivity,	 specificity,	
and positive and negative predictive values18 of the accuracy of the 
clinical	prediction	by	HCW	of	the	presence	P. aeruginosa	in	DFIs.	As	
secondary	outcomes,	we	stratified	these	results	for	seven	individual	
substrata:	 (1)	 prediction	before	 and	after	 the	 interim	 results	pres-












nonpseudomonal	 DFI	 controls,	 which	we	 considered	 sufficient	 to	
compute the predictive value of a diagnostic guess.18
We	 compared	 groups	 using	 the	 Pearson	 chi-	square	 test	 and	
evaluated changes in the prediction performance over time with 
the	P-	for-	trend	 test.	We	performed	an	unconditional,	multivariate	




had	daily	professional	experience	 in	 the	 field	of	DFI	management.	
We introduced all independent variables into the multivariate anal-
ysis and checked for collinearity and effect modification with inter-
action	 terms.	We	 used	 STATA™	 software	 (15.0)	 and	 considered	 p 
values	≤	.05	(two-	tailed)	as	significant.	The	STATA™	command	“lroc”	
printed	the	receiver	operating	characteristic	(ROC)	curve	regarding	
the accuracy of our predictions.
3  |  RESULTS
3.1  |  Healthcare workers
Overall,	13	different	specialized	HCWs	(six	nurses,	 four	orthopae-
dic	 surgeons,	 two	 internists	 and	 one	 infectious	 diseases	 special-







with more visual (n	=	38;	38/221;	17%)	 than	olfactory	predictions	
(n	 =	 28;	 13%).	 The	 proportions	 of	 olfactory	 predictions	 in	 terms	
of suspected P. aeruginosa were similar between female and male 
HCWs	(10/55	vs	18/138;	p	=	.43).	Based	on	our	individual	interviews	
of	participants,	the	most	frequent	elements	they	used	in	favour	of	
the presence of Pseudomonas spp. were a green colour in the wound 
or macerated skin. The presence of a characteristic smell was the 
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least cited element. This order did not change after our presentation 
to	the	HCWs	of	the	preliminary	results.
3.2  |  Patients and infections
We	 included	 221	 DFI	 evaluations	 (121	 of	 which	 were	 episodes	
of	DFO)	 that	occurred	 in	88	 individual	 adult	patients	 (41	 (19%)	of	
which	were	in	female	patients),	with	and	without	concomitant	foot	
ischaemia. Culture specimens grew P. aeruginosa in 22 cases (over-
all	prevalence	10%;	six	were	DFOs	and	six	were	monomicrobial	in-
fections).	 All	 monomicrobial	 infections	 due	 to	 Pseudomonas were 
from	a	specimen	of	bone	(ie	cases	of	DFO).	 In	the	100	exclusively	





12%)	 and	Enterobacter	 spp,	 (n	 =	 18;	 8%).	Overall,	 specimens	 from	
51	DFIs	(23%)	grew	Gram-	negative	bacteria.	The	delay	in	return	of	
the microbiological results lagged between 2 and 4 days. This delay 
was indifferent for cultures with and without pseudomonal involve-
ment.	In	77	episodes	(77/221;	35%),	the	patients	were	taking	empiri-
cal	oral	antibiotic	therapy	before	the	wound	sampling,	including	the	




3.3  |  Performances of the predictions
The clinicians predicted the following: the clinical involvement of 
Pseudomonas	 correctly	 in	 seven	 cases	 (true-	positive);	 its	 absence	
correctly	 in	 167	 episodes	 (true-	negative);	 its	 presence	 incorrectly	
in	32	cases	 (false-	positive);	or	 incorrectly	missed	the	Pseudomonas 
in	15	cases	(false-	negative).	Thus,	the	calculated	performance	char-
acteristics for identifying Pseudomonas in the entire study popula-
tion	 were	 as	 follows:	 sensitivity,	 0.32;	 specificity,	 0.84;	 positive	
predictive	 value,	 0.18;	 and	 negative	 predictive	 value,	 0.92.	 If	 we	
consider	true-	positive	and	true-	negative	predictions	as	correct,	then	
the	combined	proportion	of	 correct	prediction	was	79%	 (174/221	
episodes).	 The	 comparison	 between	 the	 visual	 and	 olfactory	 pre-
dictions in terms of the presence of P. aeruginosa	 in	DFIs	 revealed	
similar	performances	(8/30	vs	8/20;	p	=	.48).	The	reported	correct	





predictions for Pseudomonas are resumed in Table 1.
3.4  |  Improvement of prediction over time?
We	 assessed	 the	 overall	 prediction	 performance	 over	 the	 2-	year	
study period in three ways: by stratifying between baseline val-
ues and those after the 1st and then the 2nd presentations of the 
interim	results	 to	the	HCWs,	and	by	dividing	the	entire	study	 into	
F I G U R E  2 Receiver	operating	characteristic	(ROC)	curve	of	
the performance of the predilection of Pseudomonas aeruginosa 
in diabetic foot infection
TA B L E  1 Performance	characteristics	of	predictions	of	the	involvement	of	Pseudomonas aeruginosa in a diabetic foot infection (with 
stratifications)





Overall	prediction	in	the	entire	study	group 0.32 0.84 0.18 0.92
Before	restitution 0.38 0.82 0.28 0.88
After	the	1st	restitution	of	results 0.22 0.85 0.12 0.94
Prediction	in	osteomyelitis	cases	only 0.20 0.81 0.09 0.92
Prediction	by	female	healthcare	workers	only 0.40 0.82 0.18 0.94
Prediction	by	surgeons	only 0.36 0.84 0.25 0.90
Cases	with	Gram-	negative	rods	seen	on	Gram-	stained	smear 0.60 0.71 0.50 0.79
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consecutive blocks of forty or fifty predictions. Neither the presen-
tations nor the time spent seeing patients for the study was associ-
ated with improvement in the accuracy of prediction of the presence 
of Pseudomonas	in	the	DFI	(Table	1;	Figure	3).	The	P-	for-	trend	results	
were	negative,	with	a	p = .44 for the blocks of 40 predictions and 
with a p	=	.46	for	50	consecutive	episodes,	respectively.
3.5  |  Variables associated with a correct prediction
Besides	 the	clinical	prediction	 in	different	stratifications,	we	won-
dered whether any single variables would be significantly associated 
with	 the	 correct	 (true-	positive	 and	 true-	negative)	 prediction.	 Our	
findings on potential associations of a variety of factors with isola-
tion of P. aeruginosa	are	shown	 in	Table	2.	 In	Table	3,	we	adjusted	
for	the	case	mix	and	provide	the	results	of	univariate	and	multivari-
ate	 logistic	 regression	 analyses	with	 the	 outcome	 “correct	 predic-
tion.”	We	found	that	none	of	these	variables	was	more	associated	






nonsignificant	 goodness-	of-	fit-	test	 validated	 our	 final	 multivariate	
model (p	=	.41).
3.6  |  Value of the Gram- stained smear
Pseudomonas aeruginosa	 is	a	Gram-	negative	 rod.	During	 the	study,	
the	involved	HCWs	were	unaware	of	the	results	of	the	Gram-	stained	
smear of the specimens submitted for culture. We were interested 
in the hypothetical knowing whether the results of the Gram stain 
could	 theoretically	 improve	 the	 HCWs'	 clinical	 prediction.	 The	










In	 our	 tertiary	 centre	 highly	 specialized	 in	 the	 management	 of	
DFIs,	 the	visual	 and	olfactory	performance	of	 experienced	HCWs	
in predicting Pseudomonas	 involvement	 in	DFI	was	moderate,	with	
a	much	better	 specificity	 (approximately	 80%–	85%)	 than	 sensitiv-
ity	 (10%–	20%).	Furthermore,	 the	 likelihood	of	 correctly	predicting	
the presence of Pseudomonas did not improve during the 2 years 
we	ran	 the	study	or	after	 the	HCWs	making	 the	predictions	were	
given presentations on the preliminary results of the study. The 









tect the ability of clinical findings to predict the clinical involvement 
of Pseudomonas spp.
Considering	that	this	is	an	important	clinical	question,	it	is	surpris-
ing that we could find no publication that previously addressed this 
issue in the medical literature. There are certainly many published 
F I G U R E  3 The	proportions	of	the	
correct prediction of Pseudomonas 
aeruginosa in diabetic foot infections 
(vertical	axis)	over	the	study	period.	
Horizontal	axis;	stratified	in	blocks	of	40	
consecutive episodes. The arrows indicate 
the timing of the feedbacks of the interim 
results
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microbiological	surveys	of	DFIs	 in	various	geographical	settings,	but	
none investigated the performance of the clinical factors widely used 
by clinicians when tailoring their initial empirical antibiotic choice. The 
importance of this question is clear when studies have found that 
P. aeruginosa	is	a	pathogen	in	DFI	in	up	to	40%–	50%	DFIs.2 While many 
clinicians believe that the presence of a green colour or grape juice 
smell portends Pseudomonas,	the	only	well-	established	clinical	sign	of	
P. aeruginosa infection is ecthyma gangrenosum.20 This rare and fulmi-
nant	infection	associated	with	pseudomonal	sepsis	is	characterized	by	
round erythematous macules and patches that develop into central 
pustules	with	surrounding	erythema,	then	haemorrhagic	vesicles	and	
eventually a gangrenous ulcer with a black eschar.9	 It	 is	very	rare	 in	
the	DFI	and	usually	occurs	in	the	extremities	of	immune-	suppressed	
patients,20 including in children.9
Pseudomonas aeruginosa bacteria are known to produce pig-
ments	 such	 as	 pyoverdine	 (a	 yellow-	green	pigment;	 see	 Figure	1),	
pyocyanin21	and	pyochelin	(a	blue-	green	pigment).	These	can	com-
bine	to	produce	a	green	colour	in	wounds,8 as well as the characteris-
tic	smell	of	2-	amino-	acetophenone	when	present	in	high	amounts.22 
But,	 it	 is	unclear	whether	these	factors	are	clinically	useful	 in	pre-
dicting the presence of Pseudomonas	 in	 infected	wounds.	 Indeed,	
many	soft-	tissue	 infections,	and	practically	all	osteoarticular	 infec-
tions caused by Pseudomonas,23 lack the green colour. Several com-
panies	have	developed	expensive	tools	designed	to	help	visualize	the	
greenish colours purported to suggest the presence of Pseudomonas 
on	 the	wound	 surface,	 or	 to	 detect	 the	 supposedly	 characteristic	
smell of P. aeruginosa	with	whole-	cell	biosensors.22	Using	these	tools	
is,	however,	time-	consuming,	cumbersome	and	expensive,	and	they	
have not yet been proven to be useful.22
We conducted this study in a large referral centre with special 







n = 47 n = 174
Prior	antibiotic	use 17	(36%) .83 60	(34%)




Prediction	by	surgeon 19	(40%) .92 69	(40%)













TA B L E  2 Associations	with	a	correct	
prediction	(true-	positive	or	true-	negative	
results)	for	Pseudomonas aeruginosa 
involvement in a diabetic foot infection



















TA B L E  3 Results	of	logistic	regression	
analyses of the correct prediction of 
Pseudomonas aeruginosa involvement in 
a diabetic foot infection by associated 
factors
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factors that might influence the usefulness of the clinical fac-
tors	we	 assessed.	Nevertheless,	we	 think	 there	 are	 eight	 issues	
that may have posed limitations for our study. First,	 predicting	
the	causative	pathogen	 in	an	 infection	 involves	a	mix	of	various	
concomitant objective and subjective interpretations. While one 
clinician	 might	 prefer	 the	 visual	 aspects,	 another	 might	 rely	 on	
the	odour	or	on	the	colour	of	 the	removed	dressings.	Moreover,	
HCWs	 often	 also	 rely	 on	 the	 patient's	 history	 (eg	 assuming	 a	
higher risk for Pseudomonas in the presence of ongoing antibiotic 
therapy,	wound	maceration	or	foot	ischaemia).	We	did	not	solicit	
the	exact	reasons	HCWs	used	in	the	prediction	for	every	individ-
ual	 episode,	 although	 in	 our	 discussion	with	 them	 the	 visual	 as-
pects were predominant.
Secondly,	we	do	not	consider	any	potential	 intra-	observer	con-
sistency.	 It	 would	 have	 been	 interesting	 if	 we	 had	 been	 able	 to	
determine	whether	 the	 same	HCW	would	make	exactly	 the	 same	
prediction for a wound (eg by assessing a photograph of the wound 
several	weeks	later)	in	the	same	way.	This,	however,	was	not	practi-
cable in our study of patients undergoing routine clinical care.
Thirdly,	we	are	fortunate	to	be	in	a	resource-	rich	care	setting	
with	 a	 relatively	 low	 prevalence	 of	 pseudomonal	 DFIs	 (about	
10%).	 It	 is	 possible	 that	 other	 teams,	 in	 resource	 scare	 settings	
with a higher prevalence of Pseudomonas	 infections,	would	have	
achieved a better taste of correct predictions. With the growing 
importance	 of	 antibiotic	 stewardship	 in	managing	DFI,	we	 think	
determining whether the cheap and relatively easy clinical pre-
diction of Pseudomonas	in	DFI	is	accurate	and	worth	to	be	further	
investigated.1
Fourthly,	we	only	 formally	presented	 the	 results	of	 the	HCW's	
performance to them at the two sessions conducted during the 
study,	but	we	continuously	performed	a	feedback	of	the	results	be-
tween	these	two	time-	points.	Furthermore,	interested	HCWs	could	





produced	 better	 predictions.	However,	 our	HCWs	were	 not	 inex-
perienced and should not have needed substantial teaching in this 
assessment.	 For	 such	 groups,	 an	 iterative	 presentation	 seems	 an	
appropriate way to improve the individual performance.24 We think 
the more likely reason for our moderate performance is the genuine 
difficulty to clinically detect Pseudomonas spp. in the infected dia-
betic foot.
Fifthly,	 the	 study	 stretched	 over	 2	 years.	 Although	 we	 asked	
every	HCW	individually,	we	cannot	exclude	 the	 likelihood	that	 in-
dividuals	were	 influenced	 by	 their	 peers,	with	whom	 they	 closely	
work.	This	may	lead	to	a	kind	of	“group	think,”	leading	to	the	clinical	





determine whether the prediction was improved by using technical 
gadgets for the visual or olfactory identification of Pseudomonas. 
This	would	likely	have	strongly	influenced	the	HCWs	clinical	judge-
ment and introduced a major bias. We were interested in estimat-
ing	the	value	of	just	the	clinical	findings,	without	or	supplementary	




all Pseudomonas	 spp.	 in	DFI	with	 the	correct	empirical	agent	 from	
the	start,	as	one	pathogen,	for	example	the	P. aeruginosa,	can	be	a	
colonizer	 in	 the	 concomitant	 involvement	 of	 other	 true	 infecting	
pathogens.	Even	if	our	study	intended	to	separate	colonization	from	
active	clinical	 infection	as	much	as	possible,	we	cannot	express	on	
the pathogenic activity or the proportion of pseudomonal damage 
in	 polymicrobial	 DFIs.	We	 additionally	 believe	 that	 not	 all	 patho-
gens	 need	 specific	 antimicrobial	 coverage	 in	 DFIs.	 For	 instance,	
DFIs	may	resolve	when	patients	are	treated	with	antibiotics	that	do	
not cover selected bacteria (including Pseudomonas20 and entero-
cocci25,26).	Certainly,	experts5 acknowledge that every proven deep 
Pseudomonas	 infection	 of	 bone,	 and	 serious	monomicrobial	 infec-
tions	of	the	soft	tissue,	requires	targeted	antibiotic	treatment,23,27 
whereas	many	chronic,	ischaemic	and	polymicrobial	soft-	tissue	DFIs	




the initial microbiological diagnostic prediction. The associated key 
questions	are	basing	on	the	harms	provoked	by	a	false-	positive	or	




aspects that antibiotic stewardship wants to avoid.1	A	false-	negative	
prediction leads to a delay of 2– 4 days regarding the correct antibi-





is	 indicated,	and	not	only	because	of	P. aeruginosa.4	 In	contrast,	 in	
mild	to	moderate	soft-	tissue	DFIs,	or	in	all	chronic	DFOs,29 a delay 
of 2– 4 days before the complete targeting of all pathogens usually 
does not alter the overall outcome in the multifaceted setting of 
chronic,	polymicrobial	DFIs,	especially	not	when	there	is	a	large	sur-






already	 published	 regarding	 various	 implant-	related	 orthopaedic	
infections.30
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5  |  CONCLUSION
We	 attempted	 to	 answer	 a	 very	 important	 question,	 specifi-
cally how good are clinicians in predicting the involvement of 
Pseudomonas	spp.	in	DFI.	We	used	a	prospective	methodology	that	
spanned	a	2-	year	period.	Regrettably,	as	anticipated,	clinicians	are	




tivity.	 Presenting	 the	 interim	 results	 of	 our	 study	 to	 the	 HCWs	
did not improve their prediction scores. We believe the perfor-
mance characteristics of these clinical signs alone are too low to 
use	them	to	tailor	an	initial,	empirical	antibiotic	regimen	for	DFIs,	
which should base on infection severity rather than on the pseu-
domonal	 guess.	However,	when	 all	 clinical	 findings	 are	 negative	
this	 could	 be	 used	 in	 a	 population	with	 low	 pre-	test	 probability	
to largely rule out a Pseudomonas infection. The advantages of 
tailoring the initial empirical antibiotic coverage for pseudomonal 
DFI	 based	 on	 the	 results	 of	 the	 cheap	 and	 rapid	 clinical	 assess-
ment	remain	tempting.	In	the	light	of	the	great	need	for	antibiotic	
stewardship	facing	to	help	address	the	ever-	increasing	problem	of	
antibiotic	resistance,1 we would like to see our study repeated in a 
high-	prevalence	setting.	As	the	positive	and	the	negative	predic-
tive	values	depend	on	the	prevalence,	the	benefits	of	the	clinical	
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